Final thoughts and moving forward
Chowdhury, Elias, and fellow researchers hope that with larger controlled studies and with time, they will be able to verify exactly how microRNA profiles change as the risk of ovarian cancer rises over a period of time. They are especially interested in determining whether the new blood test they have introduced for the early detection of ovarian cancer will be useful for women at high risk of the disease, particularly women who are young and who want to have children, as well as for the general population.
“We have reached a pivotal point in our study where interested partners are ready to give us samples – we need to be prepared to organize and proceed with the project. The fact that we found something that seems exciting and worth following up is what I would call success. We will continue with our efforts to give early detection the significance it deserves. Difference between early detection vs. late is dramatic. It would make a world of difference if we could focus more on early detection and give it as much importance as drug development,” stated Chowdhury.